News stories about Amgen (NASDAQ:AMGN) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amgen earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 47.5235850554175 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

Amgen (NASDAQ AMGN) opened at $177.47 on Thursday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The company has a market cap of $128,830.00, a price-to-earnings ratio of 68.79, a price-to-earnings-growth ratio of 2.15 and a beta of 1.42. Amgen has a one year low of $152.16 and a one year high of $201.23.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. During the same quarter last year, the business posted $2.89 earnings per share. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. equities analysts anticipate that Amgen will post 13.22 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.98%. This is an increase from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is 178.29%.

Amgen announced that its board has authorized a stock repurchase program on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its shares are undervalued.

A number of brokerages have issued reports on AMGN. Leerink Swann reaffirmed a “market perform” rating on shares of Amgen in a report on Friday, February 2nd. Atlantic Securities lowered shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price objective for the company. in a report on Monday. Royal Bank of Canada cut their price objective on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a report on Thursday, October 26th. Oppenheimer set a $205.00 price objective on shares of Amgen and gave the company a “buy” rating in a report on Friday, January 5th. Finally, BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Sixteen investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $191.49.

In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total transaction of $283,070.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 4,575 shares of company stock valued at $814,396. Corporate insiders own 0.19% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Amgen (AMGN) Earns News Sentiment Score of 0.05” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2018/02/08/amgen-amgn-earns-news-sentiment-score-of-0-05.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Insider Buying and Selling by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.